BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28031082)

  • 21. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Clin Rheumatol; 2007 Feb; 26(2):161-7. PubMed ID: 16565894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
    Tseng LN; Sheu WH; Ho ES; Lan HH; Hu CC; Kao CH
    Metabolism; 2006 Jun; 55(6):741-7. PubMed ID: 16713432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of serum sclerostin and polymorphisms in the SOST gene with bone mineral density and markers of bone metabolism in postmenopausal Chinese women.
    He J; Zhang H; Wang C; Zhang Z; Yue H; Hu W; Gu J; Fu W; Hu Y; Li M; Liu Y; Zheng H; Zhang Z
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E665-73. PubMed ID: 24423318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of Serum Osteocalcin and Polymorphisms of the Osteocalcin Gene with Bone Mineral Density in Postmenopausal and Elderly Chinese Women.
    Zhang XY; He JW; Fu WZ; Liu YJ; Zhang ZL
    J Nutrigenet Nutrigenomics; 2016; 9(5-6):231-242. PubMed ID: 28002816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
    Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
    J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
    Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
    Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
    Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
    Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis].
    Wang C; He JW; Qin YJ; Zhang H; Hu WW; Liu YJ; Zhang ZL
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2958-62. PubMed ID: 20137703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Aging Clin Exp Res; 2005 Apr; 17(2):157-63. PubMed ID: 15977465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone Turnover Markers and Bone Mineral Density to Predict Osteoporotic Fractures in Older Women: A Retrospective Comparative Study.
    Qu XL; Zheng B; Chen TY; Cao ZR; Qu B; Jiang T
    Orthop Surg; 2020 Feb; 12(1):116-123. PubMed ID: 31880071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between
    Yuan H; Wang C; Liu L; Wang C; Zhang Z; Qu S
    Pharmgenomics Pers Med; 2023; 16():925-932. PubMed ID: 37920752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.